Table 4.
Adverse events (AEs) in patients treated with first-generation antipsychotics (including depot) during the switch period
| Preferred term, n (%) | Switch period (first 28 days) | Full treatment period (26 weeks) | ||
|---|---|---|---|---|
|
|
|
|||
| Asenapine (n = 151) | Olanzapine (n = 138) | Asenapine (n = 151) | Olanzapine (n = 138) | |
| At least one AE | 69 (45.7) | 80 (58.0) | 114 (75.5) | 110 (79.7) |
| Somnolence | 13 (8.6) | 21 (15.2) | 20 (13.2) | 23 (16.7) |
| Nausea | 7 (4.6) | 3 (2.2) | 8 (5.3) | 7 (5.1) |
| Insomnia | 7 (4.6) | 5 (3.6) | 17 (11.3) | 13 (9.4) |
| Dizziness | 5 (3.3) | 5 (3.6) | 8 (5.3) | 7 (5.1) |
| Headache | 5 (3.3) | 5 (3.6) | 12 (7.9) | 12 (8.7) |
| Dyspepsia | 5 (3.3) | 2 (1.4) | 6 (4.0) | 3 (2.2) |
| Anxiety | 5 (3.3) | 1 (0.7) | 12 (7.9) | 11 (8.0) |
| Agitation | 4 (2.6) | 3 (2.2) | 9 (6.0) | 4 (2.9) |
| Dysgeusia | 4 (2.6) | 0 (0.0) | 5 (3.3) | 0 (0.0) |
| Sedation | 4 (2.6) | 4 (2.9) | 5 (3.3) | 5 (3.6) |
| Weight increase | 2 (1.3) | 17 (12.3) | 9 (6.0) | 43 (31.2) |
| Weight decrease | 0 (0.0) | 1 (0.7) | 4 (2.6) | 2 (1.4) |
| Back pain | 1 (0.7) | 4 (2.9) | 1 (0.7) | 7 (5.1) |
| Increased appetite | 1 (0.7) | 6 (4.3) | 2 (1.3) | 7 (5.1) |
| Paresthesia | 1 (0.7) | 3 (2.2) | 1 (0.7) | 3 (2.2) |
| Fatigue | 0 (0.0) | 3 (2.2) | 3 (2.0) | 3 (2.2) |
| Myalgia | 0 (0.0) | 3 (2.2) | 0 (0.0) | 3 (2.2) |